InsidersTradesSigma
Follow the Acrivon Therapeutics, Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €66.8m. The latest transaction was filed on 6 August 2026 (Cession). Among the most active insiders: Miller Mary. The full history is accessible without an account.
110
Insider Decl.
n/a
Thresholds
€24m
5 ops.
Buy Volume
€3m
9 ops.
Sell Volume
46Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 6 August 2026
Declarations110 total
1,142 shares@ US$1.57Common StockSEC:0000905148-26-003499:0
573 shares@ US$1.760.0013% mcap1.8% of flowCommon StockSEC:0000905148-26-003334:0
13,729 shares@ US$1.790.5% of flowCommon StockSEC:0000905148-26-002652:0
3,888,888 shares@ US$1.808.95% mcap17.6% of flowCommon StockSEC:0001231919-26-000396:0
558 shares@ US$1.781.9% of flowCommon StockSEC:0000905148-26-001768:0
14,265 shares@ US$1.530.5% of flowCommon StockSEC:0000905148-26-001010:0
116 shares@ US$1.634.8% of flowCommon StockSEC:0000905148-26-000939:0
217 shares@ US$1.630.6% of flowCommon StockSEC:0000905148-26-000937:0
471 shares@ US$1.633.0% of flowCommon StockSEC:0000905148-26-000936:0
723 shares@ US$1.631.5% of flowCommon StockSEC:0000905148-26-000935:0
1,302 shares@ US$1.630.0% of flowCommon StockSEC:0000905148-26-000934:0
659 shares@ US$1.982.3% of flowCommon StockSEC:0000905148-26-000281:0
49,000 shares@ US$1.6761.7% of flowCommon StockSEC:0000905148-26-000226:0
Canonical exit: 14 Apr 2026 (T+90)
8,832 shares@ US$1.698390.9% of flowCommon StockSEC:0000905148-26-000225:0
Canonical exit: 14 Apr 2026 (T+90)
10,000 shares@ US$1.721821.8% of flowCommon StockSEC:0000905148-26-000212:0
Canonical exit: 13 Apr 2026 (T+90)
19,904 shares@ US$2.301.0% of flowCommon StockSEC:0000905148-25-004179:0
59,765 shares@ US$2.242.9% of flowCommon StockSEC:0000905148-25-004127:0
490 shares@ US$2.240.0% of flowCommon StockSEC:0000905148-25-004127:1
613 shares@ US$2.242.3% of flowCommon StockSEC:0000905148-25-004128:0
403 shares@ US$2.243.8% of flowCommon StockSEC:0000905148-25-004129:0
184 shares@ US$2.240.8% of flowCommon StockSEC:0000905148-25-004130:0
99 shares@ US$2.246.3% of flowCommon StockSEC:0000905148-25-004131:0
558 shares@ US$1.811.9% of flowCommon StockSEC:0000905148-25-003637:0
284 shares@ US$1.810.9% of flowCommon StockSEC:0000905148-25-003506:0
19,905 shares@ US$1.320.6% of flowCommon StockSEC:0000905148-25-003121:0
25 of 110 declarations
Acerca de Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. es una empresa biofarmacéutica centrada en el desarrollo de terapias dirigidas para el tratamiento del cáncer. Utiliza una plataforma de biomarcadores para identificar a los pacientes que probablemente se beneficiarán de sus tratamientos.